Hospital Universitari Vall d'Hebron Research Institute — Biomedical Watch V2

Traitements8programmes

Essais4liés

Publications4liées

SourceDBlocale

Traitements

8

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
CGRP antibody or gepantThe goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor: monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) during a 2-year period observation phase.	Migraine	À vérifier	À vérifier	United States, Argentina, Chile, Colombia, Croatia, Germany, Italy, Malaysia, …	À vérifier
Effectiveness of Multicomponent Treatment for Fibromyalgia (FIBROWALK)The main objective of this study is to analyse the effectiveness of the FIBROWALK multicomponent treatment program as coadjuvant of treatment-as-usual (TAU) compared to TAU alone.	Myopathies	NA	À vérifier	Spain	À vérifier
FAST — Molecular Phenotyping of Migraine Patients According to Sex and Age Through CGRP QuantificationPatients will be asked to visit the study center 2 times, the first time for clinical assessment and a second time for sample collection. Healthy controls will only be asked to visit the study center for sample collection. A sample of blood and saliva will be collected in order to measure CGRP levels and DNA and hormone testing.	Migraine	À vérifier	À vérifier	Spain	À vérifier
PROBiMS — The Effect of a Probiotic Administration as an add-on Treatment in Multiple SclerosisIt is a randomized, double-blind, placebo-controlled clinical trial whose general objective of this study is to determine the effects of probiotic administration in multiple sclerosis patients. 80 patients with relapsing-remitting multiple sclerosis will be enrolled in the study. Patients will be randomly assigned to receive either a probiotic (n=40) or a placebo (n=40) stratified by type of medication, gender and use of hormonal contraceptive treatment. They will receive a probiotic (Lactibane Iki) or placebo sachet twice a day for six months.	SEP	Non applicable	À vérifier	Spain	À vérifier
Effectiveness of Multicomponent Treatment for Fibromyalgia (FIBROWALK)The main objective of this study is to analyse the effectiveness of the FIBROWALK multicomponent treatment program as coadjuvant of treatment-as-usual (TAU) compared to TAU alone.	Myopathies	NA	À vérifier	Spain	À vérifier
CGRP antibody or gepantThe goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor: monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) during a 2-year period observation phase.	Migraine	À vérifier	À vérifier	United States, Argentina, Chile, Colombia, Croatia, Germany, Italy, Malaysia, Norway, Poland, Portugal, Spain, Turkey (Türkiye)	À vérifier
PROBiMS — The Effect of a Probiotic Administration as an add-on Treatment in Multiple SclerosisIt is a randomized, double-blind, placebo-controlled clinical trial whose general objective of this study is to determine the effects of probiotic administration in multiple sclerosis patients. 80 patients with relapsing-remitting multiple sclerosis will be enrolled in the study. Patients will be randomly assigned to receive either a probiotic (n=40) or a placebo (n=40) stratified by type of medication, gender and use of hormonal contraceptive treatment. They will receive a probiotic (Lactibane Iki) or placebo sachet twice a day for six months.	SEP	Non applicable	À vérifier	Spain	À vérifier
FAST — Molecular Phenotyping of Migraine Patients According to Sex and Age Through CGRP QuantificationPatients will be asked to visit the study center 2 times, the first time for clinical assessment and a second time for sample collection. Healthy controls will only be asked to visit the study center for sample collection. A sample of blood and saliva will be collected in order to measure CGRP levels and DNA and hormone testing.	Migraine	À vérifier	À vérifier	Spain	À vérifier

Essais cliniques

4

Molécule	Indication / population	Phase	NCT	Titre	Statut
FAST — Molecular Phenotyping of Migraine Patients According to Sex and Age Through CGRP Quantification	Migraine	À vérifier	NCT06674772	FAST — Molecular Phenotyping of Migraine Patients According to Sex and Age Through CGRP Quantification	RECRUITING
PROBiMS — The Effect of a Probiotic Administration as an add-on Treatment in Multiple Sclerosis	SEP	Non applicable	NCT07168772	PROBiMS — The Effect of a Probiotic Administration as an add-on Treatment in Multiple Sclerosis	RECRUITING
CGRP antibody or gepant	Migraine	À vérifier	NCT07159750	EUREkA — Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine	RECRUITING
Effectiveness of Multicomponent Treatment for Fibromyalgia (FIBROWALK)	Myopathies	NA	NCT04284566	Effectiveness of Multicomponent Treatment for Fibromyalgia (FIBROWALK)	COMPLETED

Publications

4

Molécule	Indication / population	Titre	Journal	Date
Effectiveness of Multicomponent Treatment for Fibromyalgia (FIBROWALK)		The feasibility and acceptability of outdoor sessions as an add-on of an online multicomponent program (FIBROWALK) for fibromyalgia: A pilot randomized controlled trial.	Reumatologia clinica
Effectiveness of Multicomponent Treatment for Fibromyalgia (FIBROWALK)		Economic evaluation of the FIBROWALK multicomponent intervention in online and outdoor formats for fibromyalgia (The On&Out Study).	The journal of pain
Effectiveness of Multicomponent Treatment for Fibromyalgia (FIBROWALK)		Effectiveness of the FIBROWALK multicomponent therapy in online and outdoor formats for fibromyalgia: A randomized controlled trial (The On&Out study).	The journal of pain
CGRP antibody or gepant		[Pituitary adenylate-cyclase activating polypeptide (PACAP)-targeting treatment as a potential migraine prophylactic therapy].	Ideggyogyaszati szemle